Denmark: A Shared Vision
Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Denmark A/S
Orestads Boulevard 67
2300 Copenhagen S
Denmark
Phone: +45 7741 5757
Fax: +45 7741 5799
Biogen Idec (Denmark) Manufacturing Aps
Biogen Idec Allé 1
3400 Hillerød
Denmark
Phone: +45 7741 6000
Fax: +45 7741 6070
www.biogenidec.dk
Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double…
Not only can Denmark lay claim to some major life science inventions – from the design of the world’s first ever insulin pen and disposable ostomy pouch to breakthroughs in…
Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche…
When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise…
Public Health Reimagined Denmark’s total health expenditure as a share of GDP has increased moderately over the past decade with the country spending 278 billion KKR (37.2 billion euros) in…
Making Life Sciences Strategic The super-sized contribution of the life sciences sector to Denmark’s national economy can hardly be overstated. With over 100,000 professionals currently engaged in biotech and pharmaceuticals…
With decades of experience across nuclear medicine, oncology, and clinical development, Dr Nicholas Borys now leads MedTrace through a pivotal phase as interim CEO and Chief Medical Officer. The Danish…
Michael Kocher, Chief Executive Officer of Xellia, brings over 15 years of pharmaceutical industry experience to his leadership role at the Danish API manufacturer. Under his leadership since October 2023,…
At first glance, Denmark might seem an unlikely hub for pharmaceutical production. With its small size and some of the highest labour costs in Europe, manufacturers might decide to look…
Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences…
Leading GN’s Hearing division with over a decade of insight and hands-on experience, Peter Justesen has overseen the company’s evolution into a more integrated, globally attuned, and innovation-led organisation. In…
After years abroad, Radiometer’s President and CEO, Francis Van Parys, returned to Europe to lead one of Denmark’s most historic MedTech companies into its next chapter. In this interview, he…
See our Cookie Privacy Policy Here
